Periodic Reporting for period 1 - Impentri (Development of Impentri, an intravenous imatinib formulation for Covid-19 acute respiratory distress syndrome (ARDS).)

The Impentri IMI2 consortium was awarded a €3.6M grant, to re-purpose an existing licensed oncology drug, imatinib for the treatment of Acute Respiratory Distress Syndrome (ARDS) induced by COVID-19. The project was awarded the grant in response to IMI2 Call 21: Development...